A Blueprint for Translational Integrated Drug Discovery

This webinar focuses on the benefits of integrated pharma manufacturing using examples of integrated processing and packaging solutions. The webinar also highlights the key advantages of choosing a single pharma solutions provider for all manufacturing needs.

Current diagnostic methods for lower respiratory specimens typically take one to two days to identify most bacterial pathogens. During that time, clinicians must rely on guideline recommendations and clinical diagnosis to guide empiric therapy, which is not optimized based on the patient’s individual pathogen. The BioFire Pneumonia Panel will provide pathogen identification in a much shorter timeframe and may allow clinicians to optimize targeted pathogen-specific therapy sooner. The BioFire Pneumonia Panel is a rapid multiplex-PCR test that identifies 33 targets, including 18 bacteria, 8 viruses and 7 antimicrobial resistance genes from lower respiratory tract specimens in about an hour. It provides semi-quantitative results (in copies/ml) for 15 of the bacterial targets. This new feature provided by multiplex-PCR testing may help clinicians and laboratorians separate colonizing from pathogenic levels of bacteria.

Scientists are always on the hunt for new analytical approaches that will streamline the biotherapeutic characterization process and answer questions found intractable using traditional methodologies. One such technique, hydrogen deuterium exchange mass spectrometry (HDX-MS)—a biophysical tool for characterizing protein conformation and dynamics—has become an indispensable method to answer important questions concerning therapeutic protein structure, stability, and interactions. Additionally, the correlation of HDX-MS profiles for a target protein interacting with a panel of ligands has facilitated the determination of structure-function relationships, and differentiated new ligand classes based on selective binding.

Biopharmaceutical companies are increasingly challenged to create a drug pricing strategy that both rewards value and innovation, and promotes affordability and access. During this webinar, PwC’s Health Research Institute will review findings from a new global survey of industry executives, and provide analysis and commentary on key drug pricing issues, including: